Akorn, Investors Get Initial OK For $24M Accounting Deal
An Illinois federal judge granted preliminary approval Tuesday for Akorn Pharmaceuticals to pay $24 million to end class allegations the company inflated revenue figures based on faulty accounting practices....To view the full article, register now.
Already a subscriber? Click here to view full article